氯沙坦钾联合贝前列素钠治疗对减少腹透液蛋白质丢失的作用

The effect of losartan potassium combined with beprost sodium on reducing protein loss in peritoneal dialysis fluid

目的观察氯沙坦钾联合贝前列素钠治疗对减少腹透液蛋白质丢失的作用。方法选择2019年1月至2020年1月在本院行连续性非卧床腹膜透析(CAPD)的92例终末期肾脏病(ESRD)患者为研究对象,随机分为对照组和观察组,每组各46例。对照组行CAPD治疗及ESRD常规治疗;观察组在对照组治疗的基础上,给予患者口服氯沙坦钾药物以及贝前列素钠治疗。比较两组治疗前、治疗6个月后的24 h腹透液蛋白总量、血清白蛋白量、血尿素氮、血肌酐水平。结果治疗6个月后,观察组的24 h腹透液蛋白量、血尿素氮、血肌酐较治疗前下降,血清白蛋白量较治疗前增加,差异均有统计学意义(均P<0.05)。对照组的24 h腹透液蛋白量、血尿素氮、血肌酐较治疗前下降,血清白蛋白量较治疗前增加,但差异均无统计学意义(均P>0.05)。观察组的24 h腹透液蛋白量、血尿素氮、血肌酐较对照组下降,血清白蛋白量较对照组增加,差异均有统计学意义(均P<0.05)。结论氯沙坦钾联合贝前列素钠治疗能减少腹透液蛋白质的丢失,改善患者的营养状况及腹膜功能,减少腹透相关并发症,值得临床推广。

Objective To observe the effect of losartan potassium combined with beprost sodium on reducing protein loss in peritoneal dialysis fluid.Methods A total of 92 patients with end-stage renal disease(ESRD)who underwent continuous ambulate peritoneal dialysis(CAPD)in our hospital from January 2019 to January 2020 were selected as the research objects and randomly divided into the observation group and the control group,with 46 cases in each group.The control group received CAPD treatment and ESRD routine treatment.On the basis of the treatment of the control group,the observation group was treated with oral losartan potassium and berprost sodium.The 24 h dialysate protein,serum albumin,serum urea nitrogen and serum creatinine before and after 6 months of treatment were collected and compared.Results After 6 months of treatment,the 24 h peritoneal dialysis fluid protein,blood urea nitrogen and serum creatinine in the observation group were decreased compared with those before treatment,and the serum albumin was increased compared with those before treatment,and the differences were statistically significant(all P<0.05).The 24 h peritoneal dialysis fluid protein,blood urea nitrogen and serum creatinine in the control group were decreased compared with those before treatment,and the serum albumin was increased compared with those before treatment,and the differences were not statistically significant(all P>0.05).Compared with the control group,the 24 h peritoneal dialysis fluid protein,blood urea nitrogen and serum creatinine in the observation group were decreased,and the serum albumin was increased,and the differences were statistically significant(all P<0.05).Conclusions Losartan potassium combined with berprost sodium can reduce the loss of protein in peritoneal dialysis fluid,improve the nutritional status and peritoneal function of patients,and reduce the complications related to peritoneal dialysis,which is worthy of further clinical promotion.